Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Energy drinks

Burden of Heart Failure – Healthcare Animation

The BriefDevelop a video that will create an emotional response and connection strong enough to inspire HCPs to consult with Heart Failure patients more proactively and promptly.The SolutionCreate an animation...

The Good Ideas Group

- PMLiVE

Johnson & Johnson to acquire Abiomed in deal worth $16.6bn

The agreement will broaden the company’s cardiovascular technologies portfolio

- PMLiVE

Boehringer Ingelheim and HeartBeat.bio partner to accelerate heart disease treatments

Heart and circulatory diseases cause over 160,000 deaths in the UK each year

Digitizing Cardiac Rehab to Capture and Retain More Patients

Dr. Harsh Vathsangam, CEO & Co-Founder of Moving Analytics, shares his expertise on mobile health and discusses how it can be used to improve patient adherence and access to cardiac...

Impetus Digital

- PMLiVE

FDA okays Amarin’s Vascepa for cardiovascular risk reduction

Drug is on course for blockbuster sales

- PMLiVE

Amarin wins FDA advisory nod for Vascepa cardiovascular expansion

Approval likely for fish-oil derived drug following speedy review

- PMLiVE

EU citizens are living longer, but not always in good health

Report finds huge inequalities between and within countries despite higher life expectancy

Energy drinks and heart disease

Say Communications analyses the link between energy drinks and heart disease and how the issue has been covered in the media.

Say Communications

- PMLiVE

Amgen starts shipping Corlaner in US

Firm also reports healthy financial growth in the first quarter

- PMLiVE

GSK hit as darapladib flunks phase III test

Heart disease drug disappoints in late-stage trial

- PMLiVE

AZ in atherosclerosis education drive during US Heart Month

Encouraging the public to learn more about the causes of heart disease

- PMLiVE

Merck drops plans to file Tredaptive in US

Pharma company also says cardiovascular drug should not be prescribed to new patients in Europe

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links